Synonyms: SC-0062 | WX-013 | WX013
Compound class:
Synthetic organic
Comment: SC0062 is a small molecule, orally bioactive endothelin receptor A (ETA; EDNRA) antagonist. It is one of the claims in patent WO2020233694 [3]. The code name SC0062 is directly linked to the structure in EP3851435B1 [1].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
SC0062 is a clinical candidate for the treatment of nephropathies (IgA nephropathy, diabetic nephropathy) [4]. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT06819826 | A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria | Phase 3 Interventional | Biocity Biopharmaceutics Co., Ltd. | ||
NCT05687890 | A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease | Phase 2 Interventional | Biocity Biopharmaceutics Co., Ltd. | 2 |